To optimize BsAb treatment, ex vivo GD2-BsAb-armed T cells (GD2-EATs) and HER2-BsAb-armed T cells (HER2-EATs) were generated, and we assessed their safety and efficacy for the treatment of osteosarcoma. This evidence concerns the gene ERBB2 and osteosarcoma.